GlassScriptPhysician profile
Bruce J Lipschutz
NPI 1225038706
$7,775.85
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,529 · 2020: $1,332 · 2021: $1,664 · 2022: $1,060 · 2023: $1,472 · 2024: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,170.95 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,006.95 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $790.02 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $751.46 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $718.87 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $484.26 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $464.73 | 2021-2024 | |
| Pfizer INC. | $409.97 | 2019-2024 | |
| Mannkind Corporation | $323.48 | 2020-2023 | Afrezza |
| Abbott Laboratories | $300.55 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $295.64 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $288.13 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.21 | 2021-2023 | |
| Amarin Pharma, INC. | $237.83 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $224.85 | 2019-2021 | |
| Allergan, INC. | $196.74 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $150.34 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $140.47 | 2019-2021 | |
| Dexcom, INC. | $131.13 | 2021-2024 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $73.12 | 2023-2024 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $63.38 | 2022 | |
| Astellas Pharma US INC | $53.68 | 2019 | |
| Esperion Therapeutics, INC. | $51.51 | 2020-2024 | Nexletol |
| Antares Pharma, INC. | $47.87 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $46.77 | 2021 | |
| Sumitomo Pharma America, INC. | $38.05 | 2023-2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $36.63 | 2019 | |
| Xeris Pharmaceuticals, INC. | $33.02 | 2021-2022 | |
| Halozyme INC | $25.50 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.67 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.32 | 2019 | |
| Optinose US, INC. | $17.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.28 | 2022 | |
| Almatica Pharma LLC | $15.48 | 2022 | |
| Genentech USA, INC. | $13.67 | 2019 | |
| Horizon Therapeutics Plc | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Lipschutz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.